Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Neoantigen Targeted Therapies Industry Expected To Reach By 2029, Starting From 2025 Levels?
The neoantigen targeted therapies market size has seen a substantial increase in recent years. This market is projected to expand from $3.4 billion in 2024 to $4.71 billion in 2025, reflecting a compound annual growth rate (CAGR) of 38.3%. The historical growth of this market can be attributed to advancements in genomic sequencing, immunotherapy evolution, improved understanding of tumor immunology, the clinical success of checkpoint inhibitors, and progress in molecular profiling advancements.
The neoantigen targeted therapies market size is anticipated to witness significant expansion in the coming years. It is projected to reach ” $15.93 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 35.7%. This growth over the forecast period stems from advancements in bioinformatics, the expansion of precision medicine, ongoing neoantigen vaccine development, strategic therapeutic combination approaches, and biomarker validation. Notable trends anticipated during the forecast period encompass neoantigen resistance management, the emergence of neoantigen-primed adoptive cell therapies, combinatorial neoantigen-based therapies, the integration of real-world data, and enhanced predictive models.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp
What Are The Top Growth Drivers Impacting The Neoantigen Targeted Therapies Market Outlook?
The escalating occurrence of cancer cases is anticipated to drive the expansion of the neoantigen targeted therapies market. The incidence of cancer denotes the number of new cases identified within a particular population over a given period. Neoantigen-targeted therapies are frequently utilized in combination to address various cancer types. For instance, the American Cancer Society (ACS) reported 1.9 million new cancer cases in the United States in 2022, marking a notable increase from prior years. Additionally, in 2022, approximately 609,360 deaths in the US were attributed to cancer, highlighting the significant impact and severity of this disease on individuals and their families. Consequently, the rising incidence of cancer cases is fueling the growth of the neoantigen targeted therapies market.
What Are The Leading Segments Analyzed In The Neoantigen Targeted Therapies Market?
The neoantigen targeted therapiesmarket covered in this report is segmented –
1) By Type: Monotherapy, Combination Therapy
2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies
3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer
4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous
5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications
Subsegments:
1) By Monotherapy: Individual Neoantigen-Targeted Treatments
2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies; Neoantigen-Targeted Therapies Combined With Chemotherapy; Neoantigen-Targeted Therapies Combined With Targeted Therapies
Which Trends Are Impacting The Neoantigen Targeted Therapies Market?
Major companies within the neoantigen targeted therapies market are adopting a strategic partnership approach to personalize cancer therapies, aiming to overcome challenges associated with current immunotherapy in treating solid tumors. Strategic partnerships are defined as a process where companies utilize each other’s strengths and resources to achieve mutual benefits and success. For instance, in January 2023, BioNTech SE, a Germany-based biotechnology company, formed a partnership with the Government of the United Kingdom, a UK-based organization, to advance personalized mRNA cancer immunotherapies. This collaboration intends to deliver tailored treatments to as many as 10,000 patients by 2030 and encompasses several critical areas, including the development of cancer immunotherapies, research on infectious disease vaccines, and the establishment of a research and development hub in Cambridge. The initiative will leverage the UK’s clinical trial infrastructure and health data resources to enhance patient recruitment and select appropriate trial sites for BioNTech’s mRNA treatments. The company plans to initiate its initial clinical trials in the UK later this year, focusing on cancer vaccines that could potentially integrate into standard treatment protocols if their effectiveness is confirmed.
Which Leading Companies Dominate The Neoantigen Targeted Therapies Market Share?
Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report
What Are The Regional Market Dynamics Impacting The Neoantigen Targeted Therapies Industry?
North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Neoantigen Targeted Therapies Market Report:
https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp
Browse Through More Reports Similar to the Global Neoantigen Targeted Therapies Market 2025, By The Business Research Company
Blood Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report
Cancer Biologics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report
Rituximab Biosimilar Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model